Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tear proteins and mucins are a heterogeneous group of molecules that constitute the aqueous and mucous layers of the precorneal tear film. Mucins, such as the secreted MUC5AC and membrane-associated MUC1, MUC4, and MUC16, are essential for reducing friction during blinking and maintaining a stable, hydrophilic ocular surface [1][2]. Tear proteins, including lysozyme, lactoferrin, and secretory IgA, provide the primary innate and adaptive immune defense against ocular pathogens [3]. These components work synergistically to prevent desiccation and protect the corneal epithelium from environmental insults. In conditions like dry eye disease, the concentration and quality of these components are often diminished, leading to tear film instability and inflammation [1]. Pharmacological interventions like rebamipide and diquafosol target these components by stimulating their endogenous production to restore the ocular surface microenvironment [4][5].
Stimulation of mucin secretion from conjunctival goblet cells and upregulation of membrane-associated mucin expression to stabilize the tear film and protect the ocular surface.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tear proteins and mucins.